Thomas Wessel0:54
I'm happy to. First, welcome to Evonik Industries. We've known each other for several years through Case, and I'm always keen on new topics and developments, especially from smaller startups. That was our connection, and we've worked together very well. Today I'm pleased to explore this new topic with you. Let me briefly introduce Evonik: we produce specialty chemicals—small ingredients, molecules that give our customers' products specific properties. We have about 32,500 employees and generate around €13 billion in revenue. Our EBITDAR (earnings before interest, taxes, depreciation, and amortization) was about €2.15 billion in 2009/2010, reflecting attractive margins. Our business model of making small ingredients that create a big effect for customers and command a premium price works well, and customers are willing to pay for those specific properties.